How often have I said that when you are diagnosed with metastatic prostate cancer or when you experience a recurrence you need to move on to a specialist, a medical oncologist who specializes in the treatment of men with advanced prostate cancer? It is easier and more comfortable to stay with the known doctor, the [...]
GTx Inc. had a poster honored as one of the best posters at the 28th Annual European Association of Urology Congress held in Milan Italy March 15 2013. The poster presentation which had the very long title of “GTx-758 an ERa Agonist Reduces Serum Free Testosterone Lower than can be Achieved by Leuprolide with a [...]
The simple answer is NO, however it should change your treatment game plan. A member of one of my support groups who has been doing active surveillance for about 5 years recently reported that their current biopsy indicated that they now have perineural invasion (PNI). They did not understand what was the significance of [...]
My friend and colleague, Richard Wassersug published an article on April 4, 2013 on the on-line service, Uro-Today.com, about the lack of reliability on internet sites when they discuss hormone therapy. Dr. Wassersug is a Professor in the Department of Anatomy and Neurobiology at Dalhousie University, Canada. His research interests include the Psychosocial impact of [...]
So, you say that there is a magic bullet! A drug that will cure all types of cancer! Come on, lets get real, NO, it is not true, At Least Not Yet. I don’t usually comment on early stage (animal model) research because we simply are not rats, zebra fish, dogs or monkeys. This, I [...]
First, I must apologize for having ignored the blog over the last two weeks. I have been intensely focused on the launch of a new project that we at Malecare have been developing. It has managed to take up every available second of my time. At this moment, I am not able to describe much [...]
An alternative to standard hormone therapy (ADT) using luteinizing hormone-releasing hormone (LHRH) analogs like leuprolide (Lupron®, Eligard®), goserelin (Zoladex®), triptorelin (Trelstar®), and histrelin (Vantas®) for men with advanced prostate cancer, but often not used is estradiol (a form of estrogen). When estrogens were first used as a therapy for men with advanced prostate cancer they [...]
According to a study published in the Feb. 20 issue of the Journal of Clinical Oncology adults with cancer can experience improvements in their emotional distress levels and in their quality of life through the use of psycho-oncologic interventions, such as relaxation, individual and group psychotherapy, and psychoeducation. Hermann Faller, M.D., Ph.D., of the University [...]
We have long known that Zoledronic Acid (Zometa) decreases a man’s risk of developing skeletal-related events (SREs) in men with castration-resistant advanced prostate cancer (CRPC) and bone metastases. In a phase III study that evaluated efficacy and safety of earlier treatment with Zometa in men with advanced prostate cancer which is still castration-sensitive found that [...]
Today, I am going to make a little change in my post. Instead of discussing additional ASCO Conference abstracts of interest to men with advanced prostate cancer (I will come back to them in short order), I want to respond to the latest public outrage that has been in the media. A recent story has [...]
